Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1567249 | 0.85 | ALDH1A1 (0.60) | HIF1AKDM4EHSD17B10ALDH1A1ALOX15 | |
| SCHEMBL10209861 | 0.85 | LMNA (0.47) | KDM4EHPGDHSD17B10ALDH1A1TSHR | |
| SCHEMBL6375356 | 0.85 | FOLH1 (0.53) | FOLH1HIF1ACYP2C9KDM4EHPGD | |
| SCHEMBL5795352 | 0.84 | AKR1C3 (0.47) | HIF1ACYP2C9MAPK1KDM4EHPGD | |
| SCHEMBL1554320 | 0.84 | KDM4E (0.53) | KDM4EHPGDHSD17B10ALDH1A1TSHR | |
| SCHEMBL31455720 | 0.83 | MRGPRX4 (0.46) | MAPK1KDM4EHPGDHSD17B10CLCN2 | |
| SCHEMBL13687539 | 0.82 | KDM4E (0.43) | KDM4EHPGDHSD17B10ALDH1A1TSHR | |
| SCHEMBL11801059 | 0.82 | KDM4E (0.43) | KDM4EHPGDHSD17B10ALDH1A1TSHR | |
| SCHEMBL1567252 | 0.82 | TSHR (0.52) | FOLH1HSD17B10ALDH1A1TSHRLMNA | |
| SCHEMBL4243105 | 0.82 | ALDH1A1 (0.57) | FOLH1HIF1ACYP2C9KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12558341-B2 | Oral complement factor D inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250186391-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-06-12 | — | — | US | disclosed |
| CN-118480030-A | Cerebulin ligands and bifunctional compounds comprising same | 阿尔维纳斯运营股份有限公司 | 2024-08-13 | — | — | CN | disclosed |
| CN-112262134-B | Cerebulin ligands and bifunctional compounds comprising same | 阿尔维纳斯运营股份有限公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-108693701-B | Colored curable resin composition | 住友化学株式会社 | 2023-07-04 | — | — | CN | disclosed |
| CN-115340555-A | Pyridine acetamide derivative as CDK inhibitor, and preparation method and application thereof | 苏州阿尔脉生物科技有限公司 | 2022-11-15 | — | — | CN | disclosed |
| WO-2022220725-A1 | LPXH INHIBITORS AS ANTI-INFECTIVE AGENTS | ZAMARATSKI EDOUARD (SE) | 2022-10-20 | — | — | WO | disclosed |
| EP-4041238-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
| WO-2022159445-A1 | COMPOUNDS AND METHODS OF ACTIVATING LIPOPROTEIN LIPASE | METREA BIOSCIENCES, INC. (US) | 2022-07-28 | — | — | WO | disclosed |
| CN-113173924-B | Pyridine acetamide derivative as CDK inhibitor, and preparation method and application thereof | 苏州阿尔脉生物科技有限公司 | 2022-07-19 | — | — | CN | disclosed |
| EP-1581474-A1 | CHIRAL ARYLKETONES IN THE TREATEMENT OF NEUTROPHIL-DEPENDENT INFLAMMATORY DESEASES | Dompé S.P.A. (IT) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004085423-A1 | PIPERIDINE DERIVATIVES FOR THE TREATMENT OF CHEMOKINE OR H1 MEDIATED DISEASE STATE | ASTRAZENECA AB (SE) | 2004-10-07 | — | — | WO | disclosed |
| WO-2004052830-A1 | CHIRAL ARYLKETONES IN THE TREATEMENT OF NEUTROPHIL-DEPENDENT INFLAMMATORY DESEASES | DOMPE S.P.A. (IT) | 2004-06-24 | — | — | WO | disclosed |
| WO-2003035636-A2 | PROCESS FOR THE PREPARATION OF 3 - ISOCHROMANONE | SYNGENTA LIMITED (GB) | 2003-05-01 | — | — | WO | disclosed |
| EP-0906304-B1 | Process for preparing 3-isochromanone | SYNGENTA LTD (GB) | 2001-07-18 | — | — | EP | disclosed |
| WO-2000037454-A1 | METHOD FOR PRODUCING 3-ISOCHROMANONE | BAYER AKTIENGESELLSCHAFT (DE) | 2000-06-29 | — | — | WO | disclosed |
| US-6008381-A | REACTING ORTHO-TOLYLACETIC ACID WITH SULFURYL CHLORIDE IN PRESENCE OF FREE RADICAL INITIATOR AND TREATING THE FORMED 2-CHLOROMETHYLPHENYLACETIC ACID WITH A BASE | ZENECA LIMITED (GB) | 1999-12-28 | — | — | US | disclosed |
| EP-0906304-A1 | PROCESS FOR PREPARING 3-ISOCHROMANONE | ZENECA LIMITED (GB) | 1999-04-07 | — | — | EP | disclosed |
| WO-1997048692-A1 | PROCESS FOR PREPARING 3-ISOCHROMANONE | ZENECA LIMITED (GB) | 1997-12-24 | — | — | WO | disclosed |
| EP-0694605-A2 | Cyclic diesters and their use as perfuming ingredients | FIRMENICH SA (CH) | 1996-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12558341-B2 | Oral complement factor D inhibitors | CFD, CFH, CFB | FOLH1 2109/4885HIF1A 2335/4885CYP2C9 849/4885 |
| US-20250186391-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | CFD, CFH, CFB | FOLH1 2296/4885HIF1A 2039/4885CYP2C9 707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.